HOOKIPA, Roche form collaboration to develop arenaviral immunotherapy for KRAS-mutated cancers

UTSW study reveals widespread disparities in immunotherapy use for patients with advanced kidney and bladder cancers

A study led by researchers at UT Southwestern Medical Center reveals significant disparities across the country in the use of immunotherapy for patients with advanced kidney and bladder cancers.

September 06, 2024

Vol.50 No.33

Clinical Roundup

Sarclisa combination improves PFS in newly diagnosed MM in phase III trial

Data from the IMROZ phase III trial demonstrated Sarclisa (isatuximab), in combination with standard-of-care bortezomib, lenalidomide, and dexamethasone (VRd) followed by Sarclisa-Rd (the IMROZ regimen), significantly reduced the risk of disease progression or death by 40%, compared to VRd followed by Rd in patients with newly-diagnosed multiple myeloma not eligible for transplant.

August 09, 2024

Vol.50 No.32

Clinical Roundup

Distinct pattern in protein production can predict severe side effects from skin cancer treatment

An activity pattern in certain genes responsible for building proteins known as spleen tyrosine kinases can predict which melanoma patients are likely to have severe side effects from immunotherapy designed to treat the most deadly skin cancer, a study shows.

August 09, 2024

Vol.50 No.32

Drugs & Targets

FDA approves Lymphir immunotherapy for r/r CTCL

FDA has approved Lymphir (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of r/r cutaneous T-cell lymphoma after at least one prior systemic therapy.

August 09, 2024

Vol.50 No.32

Clinical Trials & Tribulations

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

At its most recent meeting, the FDA Oncologic Drugs Advisory Committee focused on perioperative clinical trials, which the agency defined as neoadjuvant phase followed by surgery and continuing with adjuvant treatment using the same experimental agent (The Cancer Letter, July 26, 2024).

IMNN-001 immunotherapy improved PFS in newly-diagnosed advanced ovarian cancer in phase II study

IMUNON Inc., a clinical-stage company in late-stage development of its DNA-mediated immunotherapy, announced positive topline results from the phase II OVATION 2 study with IMNN-001 in patients with advanced ovarian cancer.

August 02, 2024

Vol.50 No.31

HOOKIPA, Roche form collaboration to develop arenaviral immunotherapy for KRAS-mutated cancers

YOU MAY BE INTERESTED IN

UTSW study reveals widespread disparities in immunotherapy use for patients with advanced kidney and bladder cancers

Sarclisa combination improves PFS in newly diagnosed MM in phase III trial

Distinct pattern in protein production can predict severe side effects from skin cancer treatment

FDA approves Lymphir immunotherapy for r/r CTCL

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

IMNN-001 immunotherapy improved PFS in newly-diagnosed advanced ovarian cancer in phase II study

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login

HOOKIPA, Roche form collaboration to develop arenaviral immunotherapy for KRAS-mutated cancers

YOU MAY BE INTERESTED IN

UTSW study reveals widespread disparities in immunotherapy use for patients with advanced kidney and bladder cancers

Sarclisa combination improves PFS in newly diagnosed MM in phase III trial

Distinct pattern in protein production can predict severe side effects from skin cancer treatment

FDA approves Lymphir immunotherapy for r/r CTCL

Of adaptive and factorial designsA biostatistician’s interpretation of last week’s ODAC

IMNN-001 immunotherapy improved PFS in newly-diagnosed advanced ovarian cancer in phase II study

Can you spare 10 minutes to complete a survey?

Login

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC